The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...

During clinical trials, it became apparent that patients were experiencing significant weight loss. This discovery has led to ...

Bad actors are using online ads, social media and bootleg ingredients to sell fake, inaccurate and harmful versions of these ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

A new study suggests that medications like Ozempic could help reduce the risk of overdose and alcohol intoxication in people ...

FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...

Federal regulators shook up the booming weight loss drug marketplace ... Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions on the market.

A previous version of this article incorrectly stated that federal regulators inspect imitation weight-loss drugs made by compounding pharmacies. The regulators inspect pharmacy operations but do ...